Overcoming intrinsic and acquired cetuximab resistance: an in vitro study on the potential of afatinib in HNSCC cell lines

被引：0
|
作者：
De Pauw, Ines
Wouters, An
Van den Bossche, Jolien
Deschoolmeester, Vanessa
Pauwels, Patrick
Vermorken, Jan B.
Peeters, Marc
Lardon, Filip
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4102
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
    De Pauw, Ines
    Lardon, Filip
    Van den Bossche, Jolien
    Baysal, Hasan
    Pauwels, Patrick
    Peeters, Marc
    Vermorken, Jan Baptist
    Wouters, An
    CANCERS, 2019, 11 (01):
  • [2] Overcoming acquired cetuximab resistance in head and neck squamous cell carcinoma: An in vitro study on the potential of PI3K inhibition.
    Zaryouh, Hannah
    Baysal, Hasan
    Pauwels, Patrick
    Peeters, Marc
    Vermorken, Jan B.
    Lardon, Filip
    Wouters, An
    De Pauw, Ines
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
    Boeckx, Carolien
    de Beeck, Ken Op
    Wouters, An
    Deschoolmeester, Vanessa
    Limame, Ridha
    Zwaenepoel, Karen
    Specenier, Pol
    Pauwels, Patrick
    Vermorken, Jan B.
    Peeters, Marc
    Van Camp, Guy
    Baay, Marc
    Lardon, Filip
    CANCER LETTERS, 2014, 354 (02) : 365 - 377
  • [4] Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
    De Pauw, Ines
    Lardon, Filip
    Van den Bossche, Jolien
    Baysal, Hasan
    Fransen, Erik
    Deschoolmeester, Vanessa
    Pauwels, Patrick
    Peeters, Marc
    Vermorken, Jan Baptist
    Wouters, An
    MOLECULAR ONCOLOGY, 2018, 12 (06) : 830 - 854
  • [5] Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP6
    Boeckx, Carolien
    Deschoolmeester, Vanessa
    Wouters, An
    de Beeckx, Ken Op
    Pauwels, Patrick
    Vanderveken, Olivier
    van Camp, Guy
    Vanden Berghe, Wim
    Specenier, Pol
    Vermorken, Jan B.
    Peeters, Marc
    Baay, Marc
    Lardon, Filip
    CANCER RESEARCH, 2013, 73 (08)
  • [6] Nuclear factor-κB activation and cetuximab-resistance in HNSCC cell lines
    Hatakeyama, Hiromitsu
    Dahlman, Kimberly Brown
    Su, Zengliu
    Robbert, Slebos
    Pao, William
    Chung, Christine H.
    CANCER RESEARCH, 2011, 71
  • [7] Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC
    Yao, Yanli
    Wang, Yujue
    Chen, Lan
    Tian, Zhen
    Yang, Guizhu
    Wang, Rui
    Wang, Chong
    Wu, Qi
    Wu, Yaping
    Gao, Jiamin
    Kang, Xindan
    Duan, Shengzhong
    Zhang, Zhiyuan
    Sun, Shuyang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [8] Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC
    Yanli Yao
    Yujue Wang
    Lan Chen
    Zhen Tian
    Guizhu Yang
    Rui Wang
    Chong Wang
    Qi Wu
    Yaping Wu
    Jiamin Gao
    Xindan Kang
    Shengzhong Duan
    Zhiyuan Zhang
    Shuyang Sun
    Signal Transduction and Targeted Therapy, 7
  • [9] Intrinsic and acquired resistance to cetuximab in colorectal cancer patients
    Bray, Steven M.
    Lee, Jeeyun
    Kim, Seung Tae
    Ebert, Philip J.
    Calley, John N.
    Wulur, Isabella H.
    Gopalappa, Thejaswini
    Wong, Swee Seong
    Qian, Hui-Rong
    Ting, Jason C.
    Liu, Jiangang
    Willard, Melinda D.
    Aggarwal, Amit
    Novosiadly, Ruslan D.
    Kim, Hee-Cheol
    Reinhard, Christoph
    CANCER RESEARCH, 2017, 77
  • [10] Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies
    Xia-qing Xu
    Xiao-hui Pan
    Ting-ting Wang
    Jian Wang
    Bo Yang
    Qiao-jun He
    Ling Ding
    Acta Pharmacologica Sinica, 2021, 42 : 171 - 178
12345